Michael McDermott - 22 Feb 2025 Form 4 Insider Report for PFIZER INC (PFE)

Role
Executive Vice President
Signature
/s/ Lori P. Hernando, by power of atty, for Michael McDermott
Issuer symbol
PFE
Transactions as of
22 Feb 2025
Net transactions value
+$63,726
Form type
4
Filing time
25 Feb 2025, 19:38:20 UTC
Previous filing
16 Sep 2024
Next filing
28 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PFE Common Stock Options Exercise $335,641 +11,125 +15% $30.17 87,636 22 Feb 2025 Direct F1
transaction PFE Common Stock Tax liability $13,071 -497 -0.57% $26.30 87,139 22 Feb 2025 Direct F2, F3
transaction PFE Common Stock Tax liability $258,844 -9,925 -11% $26.08 77,214 22 Feb 2025 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PFE Stock Appreciation Rights Options Exercise $0 -11,125 -100% $0.000000 0 22 Feb 2025 Common Stock 11,125 $30.17 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3 Price is the closing price of Pfizer common stock on February 21, 2025.
F4 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.